Shares of the Hyderabad-based pharmaceutical ingredient company closed at ₹3,297 apiece on the NSE. The stock touched an intraday low of ₹3,276. Analysts at domestic brokerage Systematix Group are most bearish after the second quarter earnings and...
By ET Bureau | Updated:
iStock
Jefferies, Motilal Oswal, and ICICI Securities downgraded their respective ratings, while Kotak Institutional Equities cut earnings estimates and price targets.
Mumbai: Divi's Laboratories fell nearly 3.5% to the lowest in two years on Wednesday, extending losses to the fifth straight session after a number of analysts downgraded the stock citing dismal second-quarter earnings amid expensive valuations.
Shares of the Hyderabad-based pharmaceutical ingredient company closed at ₹3,297 apiece on the NSE. The stock touched an intraday low of ₹3,276.
Analysts at domestic brokerage Systematix Group are most bearish after the second quarter earnings and set a target price of ₹2,829 apiece. This implies a 14.2% fall from Wednesday's closing.
Incred Research Services expects the stock to touch ₹2,935. Jefferies, Motilal Oswal, and ICICI Securities downgraded their respective ratings, while Kotak Institutional Equities cut earnings estimates and price targets.
On aggregate, analysts lowered the price target by nearly 10% before the second quarter earnings to ₹3,573.71 per share, Bloomberg data showed. "We cut our revenue estimates by 3-4% and EPS estimates by 8-9% over FY23E-FY24E to factor in lower revenue growth resultant pressures on margins," said ICICI Securities.
Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announced2026-05-23T08:21:07Z
